H.C. Wainwright lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $3 from $5 and keeps a Buy rating on the shares. The firm cites dilution from the equity raise for the target drop. The interim TN-401 update demonstrates clinical proof-of-concept with further updates expected in the first half of 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/12/2025, According to Top Analysts
- Tenaya Therapeutics price target lowered to $8 from $9 at Chardan
- Tenaya Therapeutics 50M share Spot Secondary priced at $1.20
- FDA Lifts Hold on Tenaya’s MyPEAK-1 Trial
- Tenaya Therapeutics files to sell common stock, no amount given